RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Surface Oncology Stock

Surface Oncology Net Income 2025

Surface Oncology Net Income

-47.69 M USD

Ticker

SURF

ISIN

US86877M2098

WKN

A2JJ8Q

In 2025, Surface Oncology's profit amounted to -47.69 M USD, a -46.25% increase from the -88.73 M USD profit recorded in the previous year.

The Surface Oncology Net Income history

YEARNET INCOME (undefined USD)
2028e40.95
2027e-41.14
2026e-55.55
2025e-47.69
2024e-88.73
2023e-84.18
2022-63.59
2021-78.49
202059.3
2019-54.8
2018-6.6
2017-45.4
2016-17.5

Surface Oncology Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Surface Oncology, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Surface Oncology from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Surface Oncology’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Surface Oncology. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Surface Oncology’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Surface Oncology’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Surface Oncology’s growth potential.

Surface Oncology Revenue, EBIT and net profit per share

DateSurface Oncology RevenueSurface Oncology EBITSurface Oncology Net Income
2028e240.38 M undefined0 undefined40.95 M undefined
2027e87.96 M undefined-44.03 M undefined-41.14 M undefined
2026e25.71 M undefined-86.87 M undefined-55.55 M undefined
2025e7.95 M undefined-88.41 M undefined-47.69 M undefined
2024e0 undefined-92.32 M undefined-88.73 M undefined
2023e0 undefined-83.74 M undefined-84.18 M undefined
202230 M undefined-61.87 M undefined-63.59 M undefined
20212.69 M undefined-76.01 M undefined-78.49 M undefined
2020126.2 M undefined61.5 M undefined59.3 M undefined
201915.4 M undefined-57.4 M undefined-54.8 M undefined
201859.4 M undefined-9.2 M undefined-6.6 M undefined
201712.8 M undefined-46 M undefined-45.4 M undefined
20166.6 M undefined-18.1 M undefined-17.5 M undefined

Surface Oncology stock margins

The Surface Oncology margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Surface Oncology. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Surface Oncology.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Surface Oncology's sales revenue. A higher gross margin percentage indicates that the Surface Oncology retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Surface Oncology's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Surface Oncology's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Surface Oncology's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Surface Oncology. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Surface Oncology's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Surface Oncology Margin History

Surface Oncology Gross marginSurface Oncology Profit marginSurface Oncology EBIT marginSurface Oncology Profit margin
2028e0 %0 %17.04 %
2027e0 %-50.06 %-46.77 %
2026e0 %-337.94 %-216.09 %
2025e0 %-1,112.74 %-600.26 %
2024e0 %0 %0 %
2023e0 %0 %0 %
20220 %-206.23 %-211.95 %
20210 %-2,828.92 %-2,920.92 %
20200 %48.73 %46.99 %
20190 %-372.73 %-355.84 %
20180 %-15.49 %-11.11 %
20170 %-359.38 %-354.69 %
20160 %-274.24 %-265.15 %

Surface Oncology Aktienanalyse

What does Surface Oncology do?

Surface Oncology Inc is a biopharmaceutical company focused on researching and developing treatments for cancer patients. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts. Surface Oncology is working towards developing a new generation of immunotherapies that activate both tumor and immune cells to make the fight against cancer more effective. The company utilizes its expertise in immunology to identify and develop novel approaches to cancer treatment. The company's business model is based on a combination of internal research and development activities and collaborations with industry partners. Surface Oncology has a wide range of business partners from the pharmaceutical industry and financial investors who support the development of new products and technologies. Surface Oncology has three different divisions: research and development, clinical development, and partnerships. In the research and development division, the company works on identifying new approaches to cancer treatment and developing new products and technologies. These products are then used for evaluation in clinical trials in the clinical development division. Partnerships allow Surface Oncology to benefit from the expertise and experience of its partners, enabling faster progress in the development and commercialization of new products and technologies. The company's most well-known product is the SRF231 molecule, which is in Phase I of clinical development. It is a novel immunotherapy that aims to promote the activation of T-cells to specifically target cancer cells in the body. SRF231 was originally developed by Novartis and licensed by Surface Oncology in 2016. Surface Oncology also has a pipeline of products in preclinical development. These include the SRF617 molecule, which aims to directly attack tumor cells, and the SRF388 molecule, which targets the body's immune system to the tumor antigen TARGET. In addition to its R&D and clinical development activities, Surface Oncology has a variety of partnerships with different pharmaceutical and life science companies. In 2017, the company announced a strategic collaboration with Novartis to improve the use of immunotherapies in cancer treatment. Surface Oncology aims to revolutionize the treatment of cancer patients by developing novel immunotherapies that target the diseased tissue and activate the immune system. The company has made significant progress in the development of products like SRF231, and it has a clear vision for developing a comprehensive portfolio of cancer treatments based on the immunotherapy platform. Surface Oncology ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding Surface Oncology's Profit Margins

The profit margins of Surface Oncology represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Surface Oncology's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Surface Oncology's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Surface Oncology's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Surface Oncology’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Surface Oncology stock

How much profit has Surface Oncology made this year?

Surface Oncology has made -47.69 M USD this year.

How has the profit developed compared to last year?

The profit has increased by -46.25% compared to last year fallen

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Surface Oncology publish its earnings?

Surface Oncology publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Surface Oncology?

The profits of Surface Oncology are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Surface Oncology?

You can learn more about the earnings of Surface Oncology by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Surface Oncology pay?

Over the past 12 months, Surface Oncology paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Surface Oncology is expected to pay a dividend of 0 USD.

What is the dividend yield of Surface Oncology?

The current dividend yield of Surface Oncology is .

When does Surface Oncology pay dividends?

Surface Oncology pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Surface Oncology?

Surface Oncology paid dividends every year for the past 0 years.

What is the dividend of Surface Oncology?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Surface Oncology located?

Surface Oncology is assigned to the 'Health' sector.

Wann musste ich die Aktien von Surface Oncology kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Surface Oncology from 7/20/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/20/2025.

When did Surface Oncology pay the last dividend?

The last dividend was paid out on 7/20/2025.

What was the dividend of Surface Oncology in the year 2024?

In the year 2024, Surface Oncology distributed 0 USD as dividends.

In which currency does Surface Oncology pay out the dividend?

The dividends of Surface Oncology are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Surface Oncology

Our stock analysis for Surface Oncology Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Surface Oncology Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.